Summary & Overview
HCPCS J9600: Injection, Porfimer Sodium 75 mg
HCPCS Level II code J9600 denotes an injection of porfimer sodium, 75 mg, a photosensitizing agent used in photodynamic therapy. Nationally, use of this agent is relevant for specialty oncology and procedural services where light-activated tumor ablation or lesion treatment is indicated. Clear coding for J9600 supports accurate drug billing, appropriate site-of-service reporting, and alignment with payer policies for injectable oncologic agents.
This analysis covers major national payers: Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the code's clinical purpose and typical settings of care, along with coverage considerations and common billing practices tied to inpatient/outpatient infusion and procedural contexts. The publication summarizes national benchmarks where available, recent policy updates affecting reimbursement and prior authorization patterns, and practical coding notes for claim submission.
Key takeaways include the clinical role of porfimer sodium in photodynamic therapy, the importance of specifying the administered 75 mg dosage using HCPCS Level II code J9600, and the payer landscape that influences coverage and utilization management. Data not available in the input is identified where applicable.
Billing Code Overview
HCPCS Level II code J9600 represents an injection of porfimer sodium, 75 mg. This code describes the administration of a photosensitizing agent used in photodynamic therapy. Service type: injectable drug administration/photodynamic agent. Typical site of service: outpatient infusion center, hospital outpatient department, or specialty clinic where photodynamic therapy is performed.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult referred to an interventional pulmonology or thoracic oncology service for photodynamic therapy (PDT) of endobronchial or localized pulmonary malignancy. The patient often has a diagnosis such as early-stage central non–small cell lung cancer or endobronchial tumor causing airway obstruction, and prior imaging (CT chest and PET as indicated) and bronchoscopy have localized the lesion. Porfimer sodium is administered intravenously as a photosensitizing agent (J9600 = Injection, porfimer sodium, 75 mg) typically 24–48 hours before planned bronchoscopic light activation. The clinical workflow: pre-procedure evaluation and informed consent; baseline photosensitivity precautions and medication reconciliation; intravenous administration of porfimer sodium in an outpatient infusion suite or same-day hospital outpatient department; scheduling of bronchoscopic photodynamic therapy 24–48 hours after infusion; bronchoscopic application of activating laser light under conscious sedation or general anesthesia in the operating room or endoscopy suite; post-procedure monitoring for airway complications and photosensitivity counseling with written instructions to avoid direct sunlight and bright indoor light for the required period.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
22 | Increased procedural services | Use when the photodynamic procedure requires substantially greater work than typical (extensive additional time or complexity). |